期刊文献+

乳腺癌血清sMICA含量检测的临床意义 被引量:1

Clinical Significance of Serum sMICA in the Diagnosis of Breast Cancer
下载PDF
导出
摘要 目的检测乳腺癌血清中sMICA水平,研究其单独及联合CA153检测对于乳腺癌诊断的意义。方法 ELISA法检测56例乳腺癌血清、69例乳腺良性病血清及75例健康体检者血清中sMICA水平,分析其与临床病理参数的关系。雅培免疫发光法检测其CA153浓度,并分析其与sMICA对于乳腺癌诊断的优缺点。结果乳腺癌患者血清中sMICA及CA153浓度均显著高于乳腺良性病患者及健康体检者;其中sMICA水平与乳腺癌临床分期呈正相关,淋巴结转移者sMICA浓度显著高于未转移者,与年龄及分级无明显相关性;sMICA、CA153及两者联合检测诊断乳腺癌的敏感度分别为67.86%、71.43%和92.86%。结论 sMICA可为乳腺癌病情评价提供新的参考指标,联合CA153能提高诊断性能,降低临床漏检率。 Objective To evaluate the value of sMICA and CA153 in the diagnosis of breast cancer.Methods The serum concentration of sMICA and CA153 in the breast cancer patients(56 cases),benign breast disease patients(69 cases) and healthy women(75 cases) were detected by ELISA kit and i2000 Immunochemistry Analyzer respectively.Results The serum concentration of sMICA and CA153 in the breast cancer patients were obviously higher than those of benign breast disease patients and healthy women.The sMICA in breast cancer with TNM stage (Ⅲ + Ⅳ) were dramaticlly higher than that of TNM stage(Ⅰ + Ⅱ) (P < 0.05),and also higher in the breast cancer patients with axillary lymph node metastasis.The diagnostic sensitivity of combined measurement was 92.86%.Conclusion The combined measurement of serum sMICA and CA153 significantly increased the sensitivity for diagnosis of breast cancer and provided useful information for early diagnosis of disease in patients with breast cancer.
作者 张晓燕
出处 《医学研究杂志》 2014年第4期160-162,共3页 Journal of Medical Research
关键词 SMICA CA153 乳腺癌 sMICA CA153 Breast cancer
  • 相关文献

参考文献9

  • 1吕大鹏,徐光炜.乳腺癌普查的国内外进展[J].中国实用外科杂志,2006,26(1):68-70. 被引量:65
  • 2Sanchez-Correa B,Morgado S,Gayoso I,et al.Human NK cells in acute myeloid leukaemia patients:analysis of NK cell-activating receptors and their ligands[J].Cancer Immunol Immunother,2011,60 (8):1195-1205.
  • 3Zou Y,Stastny P.Role of MICA in the immune response to transplants[J].Tissue Antigens,2010,76 (3):171-176.
  • 4Ashiru O,López-Cobo S,Fernández-Messina L,et al.A GPI anchor explains the unique biological features of the common NKG2D-ligand allele MICA * 008[J].Biochem J,2013,454 (2):295-302.
  • 5Bedel R,Thiery-Vuillemin A,Grandclement C,et al.Novel role for STAT3 in transcriptional regulation of NK immune cell targeting receptor MICA on cancer cells[J].Cancer Res,2011,71(5):1615-626.
  • 6Kloess S,Huenecke S,Piechulek D,et al.IL-2-activated haploidentical NK cells restore NKG2D-mediated NK-cell cytotoxicity in neuroblastoma patients by scavenging of plasma MICA[J].Eur J Immunol,2010,40(1l):3255-3267.
  • 7Serrano AE,Menares-Castillo E,Garrido-Tapia M,et al.Interleukin 10 decreases MICA expression on melanoma cell surface[J].Immunol Cell Biol,2011,89 (3):447-457.
  • 8陈燕,郑瑜宏,林莺莺,胡敏华,陈岩松.原发性乳腺癌患者术前血清中糖类抗原153癌胚抗原和组织多肽特异性抗原水平与临床病理特征和预后的关系[J].中华肿瘤杂志,2011,33(11):842-846. 被引量:18
  • 9Hajian-Tilaki K.Receiver operating characteristic (ROC) curve analysis for medical diagnostic test evaluation[J].Caspian J Intern Med,2013,4(2):627-635.

二级参考文献29

  • 1Linos E, Spanos D, Rosner BA, et al. Effects of reproductive and demographic changes on breast cancer incidence in China: a modeling analysis. J Natl Cancer lnst, 2008, 100 : 1352-1360.
  • 2Harris L, Fritsche H, Mennel R, et al. American Society of Chnical Oncelogy 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol, 2007, 25:5287-5312.
  • 3Carlson RW, Allred DC, Anderson BO, et al. Breast cancer: chnical practice guidelines in oncology. J Natl Compr Canc Netw, 2009, 7 : 122-192.
  • 4Falkson HC, Van Der Watt JJ, Pomccal MA, et al. Carcincembryonic antigen in patients with breast cancer: an adjunctive tool to monitor response and therapy. Cancer, 1978, 42:1308-1313.
  • 5Mughal AW, Hortobagyi GN, Fritsche HA, et al. Serial plasma carcinoembryonic antigen measurements during treatment of metastatic breast cancer. JAMA, 1983, 249 : 1881-1886.
  • 6Einarsson R, Diagnostics B, Smeden S. TPSTM a circulating tumor marker in breast cancer. Indian J Clin Biochem, 1999, 14: 109-116.
  • 7Park BW, Oh JW, Kim JH, et al. Preoperative CA 15-3 and CEA serum levels as predictor for breast cancer outcomes. Ann Oncol, 2008, 19:6754581.
  • 8Seregni E, Coli A, Mazzucca N. Circulating tumour markers in breast cancer. Eur J Nucl Med Mol hnaging, 2004, 31 :S15-22.
  • 9Nicolini A, Tartarelli G, Carpi A, et al. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CAI5.3 panel in the early detection of distant metastases. BMC Canc.er, 2006, 6:269.
  • 10Kurebayashi J, Yamamoto Y, Tanaka K, et al. Significance of serum carcinoembryonic antigen and CA15-3 in monitoring advanced breast cancer patients treated with systemic therapy: a large-scale retrospective study. Breast Cancer, 2003, 10:38-44.

共引文献81

同被引文献5

引证文献1

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部